Janssen | Patient Daily

Janssen

Press release submission | Dec 29, 2021

Janssen Submits Biologics License Application to U.S. FDA Seeking Approval of Teclistamab for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

Press release submission | Dec 22, 2021

FDA Approves Two New Indications for XARELTO® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients

Press release submission | Aug 19, 2021

Janssen Presents Phase 1 Results for RYBREVANT™ (amivantamab-vmjw) in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutations

Press release submission | May 21, 2021

RYBREVANT™ (amivantamab-vmjw) Receives FDA Approval as the First Targeted Treatment for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Press release submission | Jan 16, 2019

JANSSEN: Announces European Commission approval of ERLEADA®(apalutamide) for non-metastatic castration-resistant prostate cancer patients who are at high risk of developing metastatic disease

Press release submission | Dec 6, 2018

JANSSEN: DARZALEX® (daratumumab) Combination Regimens Show Positive Results for Newly Diagnosed and Relapsed Patients with Multiple Myeloma

Trending

Patient Daily | Mar 14, 2025

Founder of Medfluence Advisors on healthcare marketing: 'The patient journey is more complex than ever'

Patient Daily | Mar 14, 2025

Doctor on weather-related pressure headaches: This could happen 'if you have an underlying chronic sinus disease'

C.D. Marsden | Mar 14, 2025

Solidarity Health to Musk, RFK, Jr: ‘Enforce the CMS Hospital Price Transparency Rule’